AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Treating unresectable stage III NSCLC with immuno-oncology: A clinical case study

Lecture Time
16:45 - 17:00
Speakers
  • M. Reck (Grosshansdorf, Germany)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Reck (Grosshansdorf, Germany)